Loading...

UnitedHealthcare Sacral Nerve Stimulation Coverage Update | OpenPayer

ModifiedUnitedHealthcarePolicy CS358NM.D

Sacral Nerve Stimulation for Urinary and Fecal Indications (for New Mexico Only)

This New Mexico–specific UnitedHealthcare medical policy governs use, trial, implantation, replacement, revision, and coverage criteria for sacral nerve stimulation (SNS/SNM) for adults (≥18 years) with urinary voiding dysfunction and fecal incontinence; it also states not medically necessary indications.

Policy Summary

PayerUnitedHealthcare

PolicySacral Nerve Stimulation for Urinary and Fecal Indications (for New Mexico Only)

Policy CodePolicy CS358NM.D

Change TypeClarification and minor updates (includes documentation requirements)

Effective DateDec 1, 2025

Next Review DateN/A

Key ActionObtain and include prior authorization with medical records documenting conservative therapy failure and ≥50% improvement on a screening trial to support permanent implantation.

SourceLink

POLICY UPDATE CHANGES

Added language clarifying that medical records documentation may be required to assess whether the member meets clinical criteria and listing required documentation elements.

Replaced references to 'Sacral Nerve Stimulation' with 'Sacral Nerve Stimulation (neurostimulation)'.

Added definition of 'Sacral Nerve Stimulation (SNS) [Also Known as Sacral Neuromodulation (SNM) or Urologic Nerve Stimulation]'.

Updated Clinical Evidence, FDA, and References sections to reflect most current information.

Updated related policy link for Gastrointestinal Disorders Diagnostic Procedures (New Mexico only).

≥18Applies to age

50%Screening trial success threshold

≥100 mL

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Sacral Nerve Stimulation

inv-01: SNS screening trial — Urinary

Covered when ALL of the following are met

Urinary SNS screening trial eligibility: Lower urinary tract symptoms (overactive bladder symptoms/urgency-frequency, urge incontinence, or nonobstructive urinary retention); bladder capacity of 100 mL or greater; urinary voiding dysfunction is not secondary to a neurologic disease origin (e.g., Parkinson disease, stroke, spinal cord injury, multiple sclerosis); no bladder outlet or mechanical obstruction (e.g., BPH, tumor/radiation-related obstruction, urethral stricture); symptoms refractory to conservative care (e.g., bladder training, pelvic floor rehabilitation, pharmacological therapy); individual capable of operating sacral nerve stimulating device.

Applies to individuals ≥18 years

inv-02: Permanent SNS implantation — Urinary

Covered when ALL of the following are met

Permanent SNS implantation — Urinary: All criteria for Sacral Nerve Stimulation screening trial have been met AND documented improvement in reported symptoms of 50% or greater in response to a screening trial of Sacral Nerve Stimulation.≥50% improvement

Applies to individuals ≥18 years

inv-03: SNS screening trial — Fecal Incontinence

Covered when ALL of the following are met

Fecal incontinence SNS screening trial: Symptoms refractory to conservative care (e.g., bowel training, bulking agents, pelvic floor rehabilitation, pharmacological therapy); individual capable of operating sacral nerve stimulating device; fecal incontinence not secondary to a neurologic disease origin (e.g., Parkinson disease, stroke, spinal cord injury, multiple sclerosis); fecal incontinence not secondary to constipation; lack of distorted anorectal anatomy (e.g., anorectal malformation, abscess or fistula, prior rectal surgery).

Applies to adults ≥18 years

inv-04: Permanent SNS implantation — Fecal Incontinence

Covered when ALL of the following are met

Permanent SNS implantation — Fecal Incontinence: All criteria for Sacral Nerve Stimulation screening trial for fecal incontinence have been met AND documented improvement in reported symptoms of 50% or greater in response to a screening trial of Sacral Nerve Stimulation.≥50% improvement

Applies to adults ≥18 years

inv-05: Replacement or revision

Covered when ALL of the following are met

SNS replacement/revision: Member met all initial coverage criteria for SNS implantation and the existing device is nonfunctional and either cannot be repaired or is no longer under warranty.

inv-06: Unproven / Not Medically Necessary

Unproven/Not medically necessary: Use of Sacral Nerve Stimulation (neurostimulation) for the treatment of Constipation and Chronic Pelvic Pain is considered unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

inv-07: Criteria for proceeding from test stimulation to permanent SNS

Coverage contingent on documented test-phase response and prior therapy failure as supported by clinical evidence

Standard prerequisites for SNS permanent implantation: Patient underwent staged (test) sacral neuromodulation evaluation and demonstrated test-phase success (commonly defined as ≥50% symptom improvement or return to <8 voids/day for urinary frequency). Patient has failed behavioral and at least one line of pharmacologic therapy for OAB or conservative measures for fecal incontinence/LARS.≥50% symptom improvement (test)

Multiple cited studies and systematic reviews use this threshold for test success and selection for permanent implantation.

inv-08: Guideline- and evidence-based indication groups

Coverage-aligned indications and guideline recommendations summarized from professional societies and systematic reviews in the document segments provided.

OAB / Urgency Urinary Incontinence (OAB/UUI): Offer SNS for patients with OAB/UUI who have inadequate response or intolerable side effects from pharmacotherapy and behavioral therapy and who are willing to undergo a surgical procedure; consider SNS as a third-line therapy after conservative and second-line options. A trial phase (PNE or Stage 1) is recommended to predict response; life-long surveillance after implantation is advised.

Supported by AUA/SUFU, EAU, ICS

Urinary retention / Non-obstructive urinary retention (NOUR) / Underactive bladder (UAB): SNS may be offered for select patients with idiopathic urinary retention, NOUR, or UAB refractory to conservative management; test-phase SNM is recommended for men with detrusor underactivity and no benign prostatic obstruction. Patient selection should consider cystometric capacity and detrusor contractility where available.

Supported by EAU and individual studies

Fecal Incontinence (FI) and Low Anterior Resection Syndrome (LARS): SNS should be considered for individuals with FI who do not respond to conservative therapy (strong recommendation by ACG); systematic reviews report high PNE response rates and overall clinical success after permanent implantation (e.g., ~77% for LARS).

inv-09: Indications and trial-to-implant criteria

Covered when ALL of the following are met:

Refractory symptoms and prior therapy

Indications: OAB with or without incontinence; urgency urinary incontinence; nonobstructive urinary retention; fecal incontinence; selected LARS per specialty guidance.
EAU, ICS, ACG/AGA/NICE

Successful trial stimulation: Patient achieves ≥50% improvement in one or more troublesome urinary or bowel parameters during a PNE or Stage 1 test period.>=50% improvement

PNE typically 7 days for bladder and 10–21 days for bowel; Stage 1 typically 2–3 weeks.

Informed consent and follow-up planning: Preoperative counseling documented including risks, need for test stimulation, probability of success, long-term commitment, need for surgical revision, and plan for life-long surveillance and battery management.

This policy excludes sacral nerve stimulation (SNS/SNM) when urinary or fecal incontinence is secondary to neurologic disease, when bladder outlet or other mechanical obstruction exists, when fecal incontinence is secondary to constipation, or when distorted anorectal anatomy (e.g., anorectal malformation, abscess/fistula, prior rectal surgery) is present. These exclusions apply to both screening trial consideration and permanent implantation decisions.

SNS replacement or revision is limited to situations where the member previously met coverage criteria and the existing device is nonfunctional and either cannot be repaired or is no longer under warranty; replacement/revision is not intended for individuals who failed to meet trial criteria originally.

Individuals with chronic refractory nonobstructive urinary retention (NOUR) who do not demonstrate an adequate response during the initial SNS test phase are generally not candidates for permanent implantation; lack of test-phase response is cited as the common reason these patients are excluded from permanent therapy.

Per the coverage criteria, permanent implantation for urinary indications requires meeting all screening-trial eligibility criteria and achieving ≥50% improvement in reported symptoms during the screening trial, so inadequate test response should be clearly documented to support denial or non-progression to permanent implant.

Use of SNS for constipation, including slow transit constipation (STC) and refractory idiopathic constipation, is not supported as standard therapy because the evidence is insufficient and conflicting. Multiple randomized and systematic reviews report mixed results, including cross-over RCTs showing no significant benefit of active stimulation versus sham in some trials.

One recent randomized trial reported short-term improvements at 6 months for SNM versus personalized conservative treatment but limitations (lack of long-term follow-up, heterogeneous populations, and variable adverse event reporting) prevent broad endorsement of SNS for chronic constipation.

Absolute contraindications include insufficient clinical response to a therapeutic trial and pregnancy. Individuals who are unable to operate the device and lack supportive caregivers are also considered contraindicated unless adequate assistance is available.

Relative exclusions include severe or rapidly progressive neurologic disease, established complete spinal cord injury, an expected need for MRI below the head, and abnormal sacral anatomy. Additionally, SNS is not indicated when symptoms are secondary to bladder outlet obstruction, mechanical causes, or distorted anorectal anatomy.

This Medical Policy is provided for informational purposes to assist interpretation of UnitedHealthcare standard benefit plans and does not constitute medical advice. Federal, state, or contractual benefit terms govern in the event of conflict with this policy.

Before applying this policy, confirm applicable federal, state, or contractual coverage requirements and obtain any required prior authorization. UnitedHealthcare may modify policies and may use third-party decision tools (e.g., InterQual®) to assist in administering benefits.

The policy designates SNS for Constipation and Chronic Pelvic Pain as unproven and not medically necessary due to insufficient high-quality evidence demonstrating safety and efficacy. As a result, these indications are not routinely covered for permanent implantation under this policy.

For constipation specifically, randomized trials and systematic reviews have produced conflicting results and methodological limitations; therefore, routine use of SNS for chronic constipation or STC remains unsupported by the current evidence base in this policy.

Evidence for SNS in chronic pelvic pain (CPP) is limited and of low quality. Systematic reviews and guidance note variable outcomes with neuromodulation for CPP and recommend additional high-quality randomized trials before SNM can be considered a standard therapy for CPP.

The International Continence Society (ICS) acknowledges limited evidence for SNM in interstitial cystitis/bladder pain syndrome and non-IC chronic pelvic pain and recommends cautious, case-by-case consideration rather than broad adoption; this policy therefore considers SNS for CPP investigational/insufficient.

Some randomized trials have failed to demonstrate a sustained treatment effect of permanent SNS implantation for refractory constipation despite initial response to temporary stimulation. For example, cross-over RCT data have shown no significant difference between active and sham stimulation in intention-to-treat analyses.

Because of these conflicting trial results and uncertainty about long-term benefit after temporary responder selection, permanent implantation following a positive temporary test is not supported as a standard approach for refractory constipation in this policy.

SNM use for several indications beyond well-established urinary and fecal incontinence has limited or low-quality evidence (e.g., interstitial cystitis/bladder pain syndrome, various forms of chronic pelvic pain, constipation where not FDA-approved). Guideline committees and systematic reviews call for further high-quality randomized studies before broader clinical adoption.

Where evidence is limited, use of SNM may be considered investigational and not medically necessary depending on payer policy; documentation of study-level evidence and rationale is required when attempting coverage for these less-supported indications.

Coding and Definitions

Procedure CPT codesCPT

0784T	Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed.
0785T	Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator.
0786T	Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed.
0787T	Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator.
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed.
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement).
64585	Revision or removal of peripheral neurostimulator electrode array.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

HCPCS/L-codesHCPCS

L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.

Diagnosis codes (urinary and fecal indications)ICD-10

N32.81	Overactive bladder.
N32.9	Bladder disorder, unspecified.
N39.3	Stress incontinence (female) (male).
N39.41	Urge incontinence.
N39.42	Incontinence without sensory awareness.
N39.46	Mixed incontinence.
N39.490	Overflow incontinence.
N39.498	Other specified urinary incontinence.
R30.0	Dysuria.
R30.1	Vesical tenesmus.

1–10 of 35

1/4

Device PMA / regulatory identifiers mentionedmixed

P970004	InterStim PMA (initial InterStim approval).
S004	InterStim approval for urinary retention (supplement).
S302	InterStim Micro (most recent InterStim device clearance).
P190006	Axonics r‑SNM PMA.
P240031	Neuspera PMA (noted announcement).

inv-23: Trial response threshold — ≥ 50% improvement in reported symptoms

Trial response threshold≥ 50% improvement in reported symptoms during screening trial

Documentation supporting responseVoiding diaries, QoL questionnaires (e.g., ICIQ-OABqol) and PGI‑I may be used to document ≥50% improvement

Age applicabilityApplies to individuals ≥ 18 years

inv-24: Chronic Urinary Retention PVR threshold — ≥ 300 mL

Chronic urinary retention PVR thresholdPostvoid residual (PVR) ≥ 300 mL

Chronicity requirement

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization, Coverage Verification, and Decision‑Support Tools

Prior authorization is required for sacral nerve stimulation (SNS/SNM) services. Benefit coverage is subject to federal, state, and contractual requirements — confirm plan terms and obtain prior authorization before scheduling services.

Confirm federal/state/contractual coverage terms before use.
Obtain prior authorization as required by the member's plan and any applicable state or federal mandates.
UnitedHealthcare may use decision-support tools (e.g., InterQual) to assist in administrating benefits; authorization decisions may reference these tools.

Step Therapy

Test‑Phase Success Required for Permanent Implantation

Permanent implantation must follow a successful staged test phase. Proceed to permanent device implantation only for individuals who demonstrate a clearly documented successful test‑phase response.

Background and Clinical Context

Sacral Nerve Stimulation (SNS), also referred to as Sacral Neuromodulation (SNM) or urologic nerve stimulation, is an implanted neuromodulation therapy that modulates sacral nerve activity to treat refractory urinary conditions (overactive bladder, urgency urinary incontinence, and nonobstructive urinary retention) and fecal incontinence.

A temporary screening trial (percutaneous nerve evaluation or Stage 1 test) is used to predict response prior to permanent implant. Per policy and cited guidance, permanent implantation is considered when the patient meets trial eligibility and achieves a successful test response (commonly defined as ≥50% improvement in one or more troublesome urinary or bowel parameters).

Definitions and Terminology

inv-55: Successful test stimulation — Defined in the referenced RCT as ≥50% improvement in urinary incontinence or urinary frequency symptoms, or a return to normal voiding <8 voids/day.

Successful test stimulation definition≥50% improvement in urinary incontinence or urinary frequency symptoms or return to <8 voids/day

Evidence sourceDefined in referenced RCT and used as threshold to proceed to implant

DocumentationVoiding diaries and validated QoL measures (e.g., ICIQ‑OABqol) support assessment of response

inv-56: Responder for LARS — A 50% reduction in lower anterior resection syndrome (LARS) score during the test phase qualified participants for permanent generator implantation.

Responder for LARS during test phase50% reduction in LARS score qualified participants for permanent generator implantation